about
Genes that mediate breast cancer metastasis to the brainTumor cell dormancyTGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4Stratification and therapeutic potential of PML in metastatic breast cancerC/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells.Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.Accurate expression profiling of very small cell populations.RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiationInhibition of specific NF-κB activity contributes to the tumor suppressor function of 14-3-3σ in breast cancer.The logic of TGFbeta signaling.Mediators of vascular remodelling co-opted for sequential steps in lung metastasis.Control of glycogen deposition.Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells.Identification of NOG as a specific breast cancer bone metastasis-supporting geneEnhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis.FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growthThe metabolic co-regulator PGC1α suppresses prostate cancer metastasis.Tumour stroma-derived lipocalin-2 promotes breast cancer metastasis.TGF-β Family Signaling in Tumor Suppression and Cancer Progression.Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.MiniAp-4: A Venom-Inspired Peptidomimetic for Brain Delivery.Liver glycogen synthase but not the muscle isoform differentiates between glucose 6-phosphate produced by glucokinase or hexokinase.Shared control of hepatic glycogen synthesis by glycogen synthase and glucokinase.EPCR promotes breast cancer progression by altering SPOCK1/testican 1-mediated 3D growthUnderstanding the molecular mechanisms driving metastasis.Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.MAPK signaling control of colon cancer metastasis.Glucose 6-phosphate produced by gluconeogenesis and by glucokinase is equally effective in activating hepatic glycogen synthase.Regulation of Mammary Luminal Cell Fate and Tumorigenesis by p38α.Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.Expression of a green fluorescence protein-carrier protein into mouse spermatozoa.Mammary cancer stem cells reinitiation assessment at the metastatic niche: the lung and bone.Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH.Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells.Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer.CLK2 blockade modulates alternative splicing compromising MYC-driven breast tumors.Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)CANCERTOOL: A Visualization and Representation Interface to Exploit Cancer DatasetsIdentification of two essential glutamic acid residues in glycogen synthase
P50
Q24644008-EC7ACC81-FD09-48B7-8EEF-C31272DBF50BQ28073065-B221C50E-85C4-4FEF-91D6-2E0BD974CE56Q28275478-2B48283E-2A27-4373-94D1-0872ED542D5BQ28387589-180686EB-66DF-4C89-81D6-7C26C728A965Q33292244-461BBF2E-2F86-450F-92FF-6AA910EF64C8Q33721249-8A6A4BB2-21ED-49FD-B0F2-FA04A507129CQ33784437-A36E7AA5-CC63-4832-882E-EB7A80AE23DFQ33991449-C2EFDDB0-C9FC-427D-A94B-43D19812F90FQ34295493-52CAFF3E-ACE5-438A-AAB7-B71BBE19AC85Q34522372-9DE1801B-C148-451F-A14A-AD1847B7E229Q34618411-61DB96A5-032A-4EBD-A287-C8E245592E50Q35163977-D9C804EC-FD6B-4DCF-AB16-8FC349723872Q36006612-0F59FC7C-2A59-4BAE-9A57-F433F2849D85Q36033261-1B340D3A-B9A9-4AC7-B51C-281ED3BB4E88Q36377960-238FE567-1FD1-45D2-8125-CD017771FCFAQ36768822-C5681187-0699-4FEE-ABCD-D25CB66CC540Q36944849-C86C562F-7467-4ECF-BEBD-CD1019463E65Q38781389-5CB5FEBD-D9C4-40ED-827E-FB37FCCD1023Q39155158-F88DA2F6-5565-4D59-9F68-E67B9BDE94D1Q39216531-CBF04875-8ECF-4DE8-A1F2-97BFB4C857ADQ40402480-E1BF0B5F-9913-4355-9F56-868CB7EF6BB3Q40746417-F16401D7-1D78-4DC7-95EE-43B4CF95351BQ41775547-C424ACD2-D240-4EE0-8918-BDF9A729BB26Q42329454-D1162764-1AF2-4862-BFCF-6A3D467CB36DQ42353406-EBE59E3A-A0DD-49A0-A0CD-EAF3CAC1C708Q42506362-62201122-BA72-4C5E-A0AD-543FB8816F26Q43002710-EFF25B38-B32F-4906-856E-07ACBB0B1278Q44273181-B0050082-13F7-4E94-9CBA-2109E0109C25Q47241645-A49CAA8E-53F2-4C4D-8BEA-497D301C8D52Q47644628-2D0BD58E-C9C9-4679-AB92-BE5657137464Q48190414-DD6F120B-2FEB-4FA0-AC93-A643CCF10002Q48849604-6A3380EF-3778-4F66-94B2-E3A8C4F15169Q53480349-31B57DD7-451F-443A-A176-D2D6C0126A02Q54348724-92B38ADD-133B-4B7B-AC95-C4FFAAF5648BQ54978054-AC9C6AF1-08C3-4558-8242-C3CD2B86DF48Q54979063-48F0FE8F-6B9A-4002-8277-C52356AE5C9FQ55381826-EBED2D04-CF5A-441B-ACF6-87567D5835DCQ57954344-8A78175E-5626-46AF-92BD-1B18C73477CDQ58213426-E6F20FD0-70ED-425E-BE5E-490FFEC3D3B4Q74105319-FA825B5E-2843-48A0-B987-7A8B54D0B04E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Roger Gomis
@ast
Roger Gomis
@en
Roger Gomis
@es
Roger Gomis
@nl
Roger Gomis
@sl
type
label
Roger Gomis
@ast
Roger Gomis
@en
Roger Gomis
@es
Roger Gomis
@nl
Roger Gomis
@sl
prefLabel
Roger Gomis
@ast
Roger Gomis
@en
Roger Gomis
@es
Roger Gomis
@nl
Roger Gomis
@sl
P1053
E-9788-2016
P106
P1153
57188951886
7102212245
P21
P31
P3829
P496
0000-0001-6473-2858